Last reviewed 2026-04-19 · How we verify

PF-04217329 - High Dose

Pfizer · Phase 2 active Small molecule

PF-04217329 - High Dose is a Small molecule drug developed by Pfizer. It is currently in Phase 2 development.

At a glance

Generic name	PF-04217329 - High Dose
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure. (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-04217329 - High Dose CI brief — competitive landscape report
PF-04217329 - High Dose updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about PF-04217329 - High Dose

What is PF-04217329 - High Dose?

PF-04217329 - High Dose is a Small molecule drug developed by Pfizer.

Who makes PF-04217329 - High Dose?

PF-04217329 - High Dose is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What development phase is PF-04217329 - High Dose in?

PF-04217329 - High Dose is in Phase 2.

Manufacturer: Pfizer — full pipeline
Compare: PF-04217329 - High Dose vs similar drugs
Pricing: PF-04217329 - High Dose cost, discount & access